Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Contura International has reported encouraging results from five-year multicenter, prospective study of its soft volume filler Aquamid injections for facial soft tissue augmentation and facial contouring.
Subscribe to our email newsletter
The aesthetic outcome of injections with the Aquamid hydrogel showed that 96% of the 116 patients evaluated after five years had ‘very good’ or ‘good’ aesthetic results according to the physician investigators and 92% of the patients were ‘very satisfied’ or ‘satisfied’. The safety data in the trial showed that injection of Aquamid over a period of five years was safe with few and no unexpected adverse events. The five-year results are consistent with the data from the one-year, two-year and three- to four-year follow-up visits.
Michael Peytz, CEO of Contura, said: “Aquamid is well positioned to meet the global consumer needs for long-lasting aesthetic treatments to restore facial volume. In 2008 we expect to complete the 12-month follow-up in our US clinical trial and look forward to submitting the data to the FDA for review.”